Incorporation of spinal muscular atrophy screening into neonatal screening: an integrative review

Spinal muscular atrophy (SMA) is a genetically-caused muscular hypotonia that can be screened through neonatal screening. Screening for the disease became recommended in 2019 by the American Panel on Traceable Diseases in Childhood, for this reason this work seeks data in the scientific literature o...

Descripción completa

Detalles Bibliográficos
Autores: Arruda, Marillis Mesquita Gonçalves, Berlanga , Juliana Ferreira Ura, Souza , Sandra Coenga de, Bragato , Simone Galli Rocha, Oliveira , Nathália de, Belizário , Mirella Viviani Amaral Assis, Oliveira , Maria Inez Vaz de
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2022
País:Brasil
Institución:Universidade Federal de Itajubá (UNIFEI)
Repositorio:Research, Society and Development
Idioma:portugués
OAI Identifier:oai:ojs.pkp.sfu.ca:article/27075
Acceso en línea:https://rsdjournal.org/index.php/rsd/article/view/27075
Access Level:acceso abierto
Palabra clave:Muscular Atrophy Spinal
Neonatal Screening
Spinal Muscular Atrophies of Childhood
Newborn.
Atrofia Muscular Espinal
Triagem Neonatal
Atrofias Musculares Espinais da Infância
Recém-nascido.
Tamizaje Neonatal
Atrofias Musculares Espinales de la Infancia
Recién nacido.
Descripción
Sumario:Spinal muscular atrophy (SMA) is a genetically-caused muscular hypotonia that can be screened through neonatal screening. Screening for the disease became recommended in 2019 by the American Panel on Traceable Diseases in Childhood, for this reason this work seeks data in the scientific literature on spinal muscular atrophy and its screening in neonatal screening. The BVS, American Academy of Pediatrics and PubMed databases were used for the research, with a total of 26 selected. We found 4 countries with a pilot project for SMA screening, which used the qPCR test for screening. Asymptomatic children who were diagnosed with SMA by genetic testing and who started treatment at most 2 months of age achieved age-appropriate neuropsychomotor development, were able to sit and walk. Based on this, we conclude that early SMA screening and early treatment initiation are capable of modifying the natural history of the disease and giving children with this disease the opportunity to have age-appropriate motor development.